AP2692A - Live attenuated rotavirus vaccine for oral administration - Google Patents

Live attenuated rotavirus vaccine for oral administration

Info

Publication number
AP2692A
AP2692A AP2007004087A AP2007004087A AP2692A AP 2692 A AP2692 A AP 2692A AP 2007004087 A AP2007004087 A AP 2007004087A AP 2007004087 A AP2007004087 A AP 2007004087A AP 2692 A AP2692 A AP 2692A
Authority
AP
ARIPO
Prior art keywords
oral administration
live attenuated
rotavirus vaccine
attenuated rotavirus
vaccine
Prior art date
Application number
AP2007004087A
Other languages
English (en)
Other versions
AP2007004087A0 (en
Inventor
Vincent Van De Velde
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34385675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2692(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AP2007004087A0 publication Critical patent/AP2007004087A0/xx
Application granted granted Critical
Publication of AP2692A publication Critical patent/AP2692A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AP2007004087A 2005-02-17 2006-02-15 Live attenuated rotavirus vaccine for oral administration AP2692A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0503337.8A GB0503337D0 (en) 2005-02-17 2005-02-17 Compositions
PCT/EP2006/001442 WO2006087205A1 (en) 2005-02-17 2006-02-15 Live attenuated rotavirus vaccine for oral administration

Publications (2)

Publication Number Publication Date
AP2007004087A0 AP2007004087A0 (en) 2007-08-31
AP2692A true AP2692A (en) 2013-07-16

Family

ID=34385675

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004087A AP2692A (en) 2005-02-17 2006-02-15 Live attenuated rotavirus vaccine for oral administration

Country Status (32)

Country Link
US (2) US8192747B2 (es)
EP (2) EP2322211A1 (es)
JP (1) JP5118977B2 (es)
KR (1) KR101319846B1 (es)
CN (2) CN103357005A (es)
AP (1) AP2692A (es)
AR (1) AR053680A1 (es)
AT (1) ATE516044T1 (es)
AU (1) AU2006215761B2 (es)
BR (1) BRPI0608877B8 (es)
CA (1) CA2598290C (es)
CY (1) CY1111916T1 (es)
DK (1) DK1863526T3 (es)
EA (1) EA012046B1 (es)
ES (1) ES2369246T3 (es)
GB (1) GB0503337D0 (es)
HR (1) HRP20110668T1 (es)
IL (1) IL184802A0 (es)
MA (1) MA29321B1 (es)
MX (1) MX2007010075A (es)
MY (1) MY145790A (es)
NO (1) NO341789B1 (es)
NZ (1) NZ560314A (es)
PE (1) PE20061094A1 (es)
PL (1) PL1863526T3 (es)
PT (1) PT1863526E (es)
SI (1) SI1863526T1 (es)
TW (1) TWI358303B (es)
UA (1) UA91044C2 (es)
UY (1) UY29377A1 (es)
WO (1) WO2006087205A1 (es)
ZA (1) ZA200706668B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132480A2 (en) * 2006-05-12 2007-11-22 Bharat Biotech International Limited A composition useful as a vaccine
EP2197283B1 (en) * 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations for preservation of rota virus
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
CA2763359C (en) 2009-05-12 2021-07-27 Baoming Jiang New human rotavirus strains and vaccines
CN101972475B (zh) * 2010-04-12 2014-04-09 李建平 一种细菌多糖-蛋白结合疫苗及其制备方法
CN101863966B (zh) * 2010-05-21 2012-10-03 中国人民解放军第三军医大学 抗轮状病毒药物作用靶标及其构建方法和应用方法
KR20170084354A (ko) 2010-09-24 2017-07-19 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
WO2012103464A2 (en) * 2011-01-28 2012-08-02 Brian Pulliam Oral thin film vaccine preparation
KR20150000389A (ko) * 2011-04-28 2015-01-02 인터내셔널 메디카 파운데이션 액상 백신 제제
CN102349932B (zh) * 2011-10-12 2012-12-26 刘壮华 一种治疗息肉的药物制剂
WO2013105105A2 (en) * 2012-01-13 2013-07-18 Serum Institute Of India Ltd. Novel viral vaccine compositions and methods for preparing such vaccines
AU2013216871B2 (en) * 2012-02-08 2017-08-17 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
AU2013228096B2 (en) * 2012-03-05 2017-07-13 Intravacc B.V. Methods and compositions for stabilizing dried biological materials
EP2945650B1 (en) * 2012-04-23 2023-07-05 Bharat Biotech International Limited Rotavirus vaccine compositions and process for preparing the same
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
MX361647B (es) 2013-03-11 2018-12-13 Univ Florida Materiales y métodos para mejorar la función pulmonar y para la prevención y/o tratamiento de complicaciones pulmonares inducidas por radiación.
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
CN103316336B (zh) * 2013-05-31 2015-01-28 北京科兴中维生物技术有限公司 一种适于口服的轮状病毒疫苗
CN103316335B (zh) * 2013-05-31 2014-11-12 北京科兴生物制品有限公司 一种适于口服的脊髓灰质炎病毒疫苗
CA2914776C (en) * 2013-07-19 2018-08-07 Hexal Ag Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
TW201601776A (zh) * 2013-10-03 2016-01-16 Nitto Denko Corp 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN104524562A (zh) * 2014-12-08 2015-04-22 武汉生物制品研究所有限责任公司 口服六价重配轮状病毒活疫苗
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
JP2019502685A (ja) * 2015-12-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 熱安定性ロタウイルスワクチン製剤およびその使用方法
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
KR20200144120A (ko) * 2018-04-16 2020-12-28 메르크 파텐트 게엠베하 열 안정성을 개선하기 위한 단백질 제제에 대한 첨가제
CN110946871A (zh) * 2019-12-12 2020-04-03 浙江华康药业股份有限公司 槐糖在制备预防和治疗肥胖产品中的应用及对应产品
CN115531364B (zh) * 2021-06-30 2024-02-23 中国科学技术大学 预防或治疗轮状病毒感染的微生物代谢物制剂及其用途
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012797A2 (en) * 1999-08-17 2001-02-22 Smithkline Beecham Biologicals S.A. Method of separating rotavirus variants and live attenuated rotavirus vaccine
WO2002011540A1 (en) * 2000-08-03 2002-02-14 Merck & Co., Inc. Rotavirus vaccine formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR0171434B1 (ko) * 1990-11-16 1999-02-01 윌리엄 케이. 슈버트 인체 로타바이러스, 백신 및 방법
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
CA2114240A1 (en) * 1991-08-05 1993-02-18 Sterling Drug Inc. Buffered formulation of peg-sod
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
EP0729473B1 (en) 1993-11-17 2000-08-23 OM Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
DK0939648T3 (da) 1996-09-26 2008-02-11 Merck & Co Inc Rotavirusvaccineformuleringer
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
CN1326564C (zh) 1997-04-01 2007-07-18 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
WO2000000462A1 (fr) 1998-06-30 2000-01-06 Om Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
ATE462446T1 (de) * 2000-01-28 2010-04-15 Us Gov Health & Human Serv Immunogenischen zusammensetzung von lebendigen rotaviren mit verringertem risiko von nebenwirkungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012797A2 (en) * 1999-08-17 2001-02-22 Smithkline Beecham Biologicals S.A. Method of separating rotavirus variants and live attenuated rotavirus vaccine
WO2002011540A1 (en) * 2000-08-03 2002-02-14 Merck & Co., Inc. Rotavirus vaccine formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VESIKARI T. ET AL.: "Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 21-22, 29 July 2004 (2004-07-29), pages 2836-2842, XP004520421, ISSN: 0264-410X, the whole document *

Also Published As

Publication number Publication date
AU2006215761A1 (en) 2006-08-24
CN101300028A (zh) 2008-11-05
PL1863526T3 (pl) 2011-12-30
HRP20110668T1 (hr) 2011-10-31
KR101319846B1 (ko) 2013-10-22
ATE516044T1 (de) 2011-07-15
ZA200706668B (en) 2009-07-29
SI1863526T1 (sl) 2011-11-30
JP5118977B2 (ja) 2013-01-16
US8192747B2 (en) 2012-06-05
MA29321B1 (fr) 2008-03-03
ES2369246T3 (es) 2011-11-28
UA91044C2 (uk) 2010-06-25
JP2008530165A (ja) 2008-08-07
AU2006215761B2 (en) 2011-03-17
MX2007010075A (es) 2008-01-16
IL184802A0 (en) 2007-12-03
MY145790A (en) 2012-04-30
NO341789B1 (no) 2018-01-22
PT1863526E (pt) 2011-10-11
DK1863526T3 (da) 2011-10-24
EP1863526A1 (en) 2007-12-12
WO2006087205A1 (en) 2006-08-24
US20080166372A1 (en) 2008-07-10
BRPI0608877A2 (pt) 2012-07-31
NO20073868L (no) 2007-11-15
AR053680A1 (es) 2007-05-16
BRPI0608877B8 (pt) 2021-05-25
CY1111916T1 (el) 2015-11-04
CA2598290A1 (en) 2006-08-24
AP2007004087A0 (en) 2007-08-31
US20120237547A1 (en) 2012-09-20
BRPI0608877B1 (pt) 2021-02-09
UY29377A1 (es) 2006-10-02
KR20070103506A (ko) 2007-10-23
US8821891B2 (en) 2014-09-02
EP2322211A1 (en) 2011-05-18
PE20061094A1 (es) 2006-11-30
NZ560314A (en) 2011-02-25
CN101300028B (zh) 2014-06-04
EP1863526B1 (en) 2011-07-13
CA2598290C (en) 2015-08-11
EA012046B1 (ru) 2009-08-28
GB0503337D0 (en) 2005-03-23
CN103357005A (zh) 2013-10-23
EA200701519A1 (ru) 2008-02-28
TW200640486A (en) 2006-12-01
TWI358303B (en) 2012-02-21

Similar Documents

Publication Publication Date Title
AP2692A (en) Live attenuated rotavirus vaccine for oral administration
HK1184057A1 (zh) 諾如病毒疫苗製劑
IL187475A0 (en) Oral dosage form comprising an antimisuse system
ZA201101523B (en) Linaclotide-containing formulations for oral administration
ZA200708634B (en) Novel vaccine formulations
EP1757273A4 (en) PREPARATION FOR ORAL ADMINISTRATION
EP1768688A4 (en) ORAL BORRELIOSE VACCINE
EP2133092A4 (en) ORAL VACCINE
GB0710439D0 (en) Oral dosage form
EP1954307A4 (en) ORAL VACCINES AGAINST MILZBRAND ON SALMONELLA BASE
EP1941896A4 (en) COMPOSITION CONTAINING A DIPEPTIDE FOR ORAL ADMINISTRATION
EP2081591A4 (en) LI-KEY REINFORCED POTENTIAL OF VACCINES
GB0911480D0 (en) Francisella strian for live vaccine
IL198760A0 (en) Oral formulations
AP2695A (en) Vaccine adjuvants
EP1713902A4 (en) LIVING ATTENUATED SALMONELLA TO BE USED FOR VACCINES
HK1115054A1 (en) Preparation for oral administration
GB0506018D0 (en) Preparation for oral administration
SI1893184T1 (sl) Oralna dozirna oblika, ki obsega sistem proti zlorabi
AU2006907050A0 (en) Rotavirus Vaccine